H. Mulroy, Director. Mr. Mulroy joined the BioTime Board during October 2014. Since June 2017, Mr. Mulroy has served as the
Chief Executive Officer of Asterias. Prior to joining Asterias, Mr. Mulroy served as a Senior Advisor to CamberView Partners,
LLC, which assists companies in connection with investor engagement and complex corporate governance issues. Mr. Mulroy served
until September 2014 as Executive Vice President - Strategic Affairs and General Counsel of the Autoimmune and Rare Diseases Business
Unit of Mallinckrodt plc following its acquisition of Questcor Pharmaceuticals, Inc. in August 2014. Mr. Mulroy was appointed
Executive Vice President, Strategic Affairs and General Counsel and Corporate Secretary of Questcor during February 2014, having
previously served as Chief Financial Officer, General Counsel and Corporate Secretary since January 2011. From 2003 to 2011, Mr.
Mulroy was employed by the law firm of Stradling Yocca Carlson & Rauth, where he served as a partner from 2004, and represented
Questcor and other publicly-traded companies. From 1997 to 2003, Mr. Mulroy was an investment banker at Citigroup and Merrill
Lynch. Mr. Mulroy also serves as a director of Asterias. From July 2011 to August 2014, Mr. Mulroy served as a member of the Board
of Directors of Comarco, Inc., which developed and designed innovative technologies and intellectual property used in power adapters.
Mr. Mulroy earned his J.D. degree from the University of California, Los Angeles and his B.A. (Economics) from the University
Redmond, Director. Mr. Redmond joined the BioTime Board during February 2018. Mr. Redmond is a seasoned healthcare strategist,
who has held a number of global leadership positions. He currently is a partner at Zarsy, LLC. His global leadership roles include:
CEO of WebMD Health Corp., where he oversaw cost rationalizations and streamlined operations to position the company for growth;
Senior Vice President and Group President, Pfizer Diversified Businesses. The Diversified Business included Animal Health, Consumer
Healthcare, Capsugel and Nutrition. While at Pfizer he also became the head of Corporate Strategy. While at Wyeth he was the first
EVP and General Manager Wyeth Biopharma and President of Wyeth Consumer Healthcare. Mr. Redmond also serves as a director of OncoCyte
Corporation and he is currently a member of the Board of Directors for the Arthritis Foundation, where he has served since 2014.
Mr. Redmond holds a MAS degree from Johns Hopkins University and a BA from the University of Maryland at College Park. He was
a 2012 recipient of The Johns Hopkins University Distinguished Alumnus Award.
C. Russell, Director. Mr. Russell joined the BioTime Board during December 2014. Mr. Russell served as the Chief Executive
Officer of Shire plc, a biopharmaceutical company, from June 2008 to April 2013. Mr. Russell served as the Chief Financial Officer
of Shire from 1999 to 2008 and also served as its Principal Accounting Officer and Executive Vice President of Global Finance.
Prior to joining Shire, Mr. Russell served at ICI, Zeneca and AstraZeneca for 19 years, most recently as Vice President of Corporate
Finance at AstraZeneca plc. He is a Chartered Accountant, having qualified with Coopers & Lybrand (now PriceWaterhouseCoopers
LLP). Mr. Russell also serves as a director of Mallinckrodt plc and Therapeutics MD, Inc., and as Chairman of the Board of Directors
of Revance Therapeutics, Inc. Mr. Russell previously served as a director of Shire plc, Questcor Pharmaceuticals, Inc. until it
was acquired by Mallinckrodt plc in August 2014, and InterMune, Inc. prior to its acquisition by Roche Holdings, Inc. during September
Officers of the Combined Company
is currently expected that the executive officers of BioTime following the Merger will be substantially similar to the current
executive officers of BioTime. In addition, following the effective time of the merger BioTime contemplates that certain employees
of Asterias will join BioTime as officers of BioTime and thus may become executive officers of BioTime. In the event that new
personnel become executive officers of BioTime, certain persons who currently serve as executive officers of BioTime may no longer
serve in such capacity. As of the date of this joint proxy statement/prospectus it is not known which Asterias employees, if any,
will become executive officers of BioTime and no determinations by BioTime have been made in this regard. Similarly, it is not
known which of BioTime’s current executive officers, if any, will cease to serve in such capacity. Any executive officers
of BioTime following the completion of the merger will serve in such capacity at the discretion of the BioTime Board. The following
table lists the names, ages and positions of the individuals who are currently serving as executive officers of BioTime.